Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia.

Non-small-cell lung cancer (NSCLC) has experienced several diagnostic and therapeutic changes over the past two decades. However, there are few studies conducted with real-world data regarding the evolution of the cost of these new drugs and the corresponding changes in the survival of these patients. We collected data on patients diagnosed with NSCLC from the tumor registry of the University Hospital of Vic from 2002 to 2021.

Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data.

Colorectal cancer (CRC) is one of the most frequent tumours and one of the major causes of morbidity and mortality globally. Its incidence has increased in recent years and could be linked to unhealthy dietary habits combined with environmental and hereditary factors, which can lead to genetic and epigenetic changes and induce tumour development. The model of CRC progression has always been based on a genomic, parametric, static and complex approach involving oncogenes and tumour suppressor genes.

and inhibition as treatment strategies in V600E metastatic colorectal cancer.

Introduction: driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of kinase and sustained pathway signaling. mutations define a sub-population characterized by a poor prognosis and dismal median survival. Following successful outcomes with inhibition in mutant metastatic melanoma, this approach was evaluated in metastatic colorectal cancer (mCRC).

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.

Introduction: Molecular profiling has led to significantly longer survival in metastatic colorectal cancer (mCRC) patients. Clinical guidelines recommend testing for KRAS/NRAS, BRAF and MSI status, and new biomarkers such as HER2 amplification and NTRK fusions have emerged more recently in refractory CRC, supported by overwhelming clinical relevance. These biomarkers can guide treatment management to improve clinical outcomes in these patients.